Jpmorgan Chase & CO Bio Affinity Technologies, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Bio Affinity Technologies, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 18 shares of BIAF stock, worth $23. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18
Previous 13
38.46%
Holding current value
$23
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BIAF
# of Institutions
16Shares Held
376KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA172KShares$228,7520.0% of portfolio
-
Geode Capital Management, LLC Boston, MA69.6KShares$92,5680.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC27.9KShares$37,0870.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny23KShares$30,5460.0% of portfolio
-
State Street Corp Boston, MA17.6KShares$23,4080.0% of portfolio
About bioAffinity Technologies, Inc.
- Ticker BIAF
- Exchange
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 2,727,580
- Market Cap $3.63M
- Description
- bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...